L. Mevellec

发表

Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.

A. Rosenwald, W. Chan, D. Weisenburger, 2015, Cancer cell.

Novel cyclobutane carbocyclic nucleosides

F. Huet, L. Mevellec, 1994 .

Substituted azoloquinolines and -quinazolines as new potent farnesyl protein transferase inhibitors.

M. Janicot, C. Meyer, G. Mannens, 2003, Bioorganic & medicinal chemistry letters.

4-methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA.

A. Saha, C. Meyer, G. Mannens, 2003, Bioorganic & medicinal chemistry letters.

Synthesis of a novel trisubstituted cyclobutane nucleoside analogue. Unexpected C4-C3 ring contractions in related reactions

F. Huet, L. Mevellec, 1997 .

Synthesis of a Novel Trisubstituted Cyclobutane Nucleoside Analogue. Unexpected C4‐C3 Ring Contractions in Related Reactions.

F. Huet, L. Mevellec, 2010 .

High selectivities in electrophilic additions to cyclobutene compounds

F. Huet, L. Mevellec, M. Evers, 1996 .

Preparation involving a C4-C3 ring contraction in the key step of a novel cyclopropane carbocyclic nucleoside

F. Huet, L. Mevellec, 1995 .

Selective Synthesis of a Novel Methylenecyclobutane Nucleoside Analogue

F. Huet, L. Bhat, L. Mevellec, 2000 .

Impact on farnesyltransferase inhibition of 4-chlorophenyl moiety replacement in the Zarnestra series.

C. Meyer, L. Mevellec, P. Angibaud, 2007, European journal of medicinal chemistry.

The first semi-synthesis of enantiopure homoharringtonine via anhydrohomoharringtonine from a preformed chiral acyl moiety☆☆☆

L. Mevellec, G. Dujardin, R. Dhal, 1999 .

Farnesyl Protein Transferase Inhibitors: Medicinal Chemistry, Molecular Mechanisms,and Progress in the Clinic

L. Mevellec, P. Angibaud, D. End, 2006 .

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

C. Murray, J. Vialard, D. Newell, 2017, Molecular Cancer Therapeutics.

Activation of RAS family members confers resistance to ROS1 targeting drugs

M. Varella‐Garcia, R. Doebele, R. Dziadziuszko, 2014, Oncotarget.

Structure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper Kinase.

V. Berdini, D. Brehmer, J. Linders, 2015, ACS medicinal chemistry letters.

JNJ-38877605: a selective Met kinase inhibitor inducing regression of Met-driven tumor models.

Tianbao Lu, M. Cummings, Dana L. Johnson, 2008 .

Abstract 4791: OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models

Tianbao Lu, G. Clack, L. Mevellec, 2018, Experimental and Molecular Therapeutics.

Discovery of an Allosteric, Inactive Conformation-Selective Inhibitor of Full-Length HPK1 Utilizing a Kinase Cascade Assay.

Robyn Miller, J. Vialard, S. Allen, 2021, Biochemistry.

Abstract 1738: JNJ-42756493 is an inhibitor of FGFR-1, 2, 3and4 with nanomolar affinity for targeted therapy

C. Murray, J. Vialard, D. Newell, 2014 .